Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas

References

• Preusser M, de Ribaupierre S, Wohrer A, et al. Current concepts and management of glioblastoma. Ann Neurol 2011;70:9–21.
   PubMed Web of Science ®Google Scholar
• Pallud J, Dezamis E, Audureau E, et al. Neuronal immunoexpression and a distinct subtype of adult primary supratentorial glioblastoma with a better prognosis. J Neurosurg 2012;117:476–85.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66.
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group . Lancet 1995;345:1008–12.
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5:79–88.
   PubMed Web of Science ®Google Scholar
• Duntze J, Litré CF, Eap C, et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann Surg Oncol 2013;20:2065–72.
   PubMed Web of Science ®Google Scholar
• Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 2008;88:353–7.
   PubMed Web of Science ®Google Scholar
• Affronti ML, Heery CR, Herndon JE 2nd, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009;115:3501–11.
   PubMed Web of Science ®Google Scholar
• Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010;33:441–9.
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110:583–8.
   PubMed Web of Science ®Google Scholar
• Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 2010;17:1740–6.
   PubMed Web of Science ®Google Scholar
• La Rocca R, Hodes J, Villanueva W, et al. (2006). A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion. Abstract presented at the Annual Meeting of the Society of Neuro-oncology, Orlando, FL (Abstract).
   Google Scholar
• Salmaggi A, Milanesi I, Silvani A, et al. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. J Neurosurg 2013;118:821–9.
   PubMed Web of Science ®Google Scholar
• Barr JG, Grundy PL. The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma. Br J Neurosurg 2012;26:818–22.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109.
   PubMed Web of Science ®Google Scholar
• Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006;24:2563–9.
   PubMed Web of Science ®Google Scholar
• Berger MS, Tucker A, Spence A, Winn HR. Reoperation for glioma. Clin Neurosurg 1992;39:172–86.
   PubMedGoogle Scholar
• Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115:3–8.
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program (2006). Common terminology criteria for adverse events. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (Accessed 27 April 2013).
   Google Scholar
• Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70:234–43.
   PubMed Web of Science ®Google Scholar
• Gallego JM, Barcia JA, Barcia-Mariño C. Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir (Wien) 2007;149:261–5.
   PubMed Web of Science ®Google Scholar
• Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41:44–8.
   PubMed Web of Science ®Google Scholar
• Miglierini P, Bouchekoua M, Rousseau B, et al. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity. Clin Neurol Neurosurg 2012;114:1222–5.
   PubMed Web of Science ®Google Scholar
• Noël G, Schott R, Froelich S, et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 2012;82:749–55.
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009;110:156–62.
   PubMed Web of Science ®Google Scholar
• Darlix A, Baumann C, Lorgis V, et al. Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res 2013;33:3467–74.
   PubMed Web of Science ®Google Scholar
• De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir (Wien) 2012;154:1371–8.
   PubMed Web of Science ®Google Scholar
• Metellus P, Coulibaly B, Nanni I, et al. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 2009;115:4783–94.
   PubMed Web of Science ®Google Scholar
• Lechapt-Zalcman E, Levallet G, Dugué AE, et al. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer 2012;118:4545–54.
   PubMed Web of Science ®Google Scholar